Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF) study design

Takashi Yokota, Arata Fukushima, Shintaro Kinugawa, Takahiro Okumura, Toyoaki Murohara, Hiroyuki Tsutsui

研究成果: Contribution to journalArticle

7 引用 (Scopus)

抜粋

Hyperuricemia is an independent predictor of mortality in patients with chronic heart failure. The aim of the study is to determine whether a urate-lowering agent febuxostat, an inhibitor of xanthine oxidase, may improve the clinical outcomes in chronic heart failure patients with hyperuricemia when compared to conventional treatment. This multicenter, prospective, randomized, open-label, blinded endpoint study with a follow-up period of 24 weeks will enroll 200 Japanese chronic heart failure patients with hyperuricemia. The eligibility criteria include a diagnosis of chronic heart failure (New York Heart Association functional class II-III with a history of hospitalization due to worsening of heart failure within the last 2 years), reduced left ventricular systolic function (left ventricular ejection fraction < 40%) and increased plasma natriuretic peptide [plasma B-type natriuretic peptide (BNP) ≥100 pg/mL or N-terminal pro BNP (NT-proBNP) ≥400 pg/mL], and hyperuricemia (serum uric acid >7.0 mg/dL and ≤10 mg/dL) at the screening visit. The primary outcome is the difference in the plasma BNP levels between the baseline and 24 weeks of treatment. The plasma BNP levels are measured in the central laboratory in a blinded manner. This study investigates the efficacy and safety of febuxostat in chronic heart failure patients with hyperuricemia.

元の言語英語
ページ(範囲)976-982
ページ数7
ジャーナルInternational heart journal
59
発行部数5
DOI
出版物ステータス出版済み - 2018

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

フィンガープリント Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF) study design' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用